Accolade Inc

ACCD

Valor de mercado US$ 576 mi

SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting”) held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission.

Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE , March 6, 2025 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) has partnered with Oshi Health , a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

Here is how Accolade (ACCD) and Casella (CWST) have performed compared to their sector so far this year.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQ: ACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders. Halper Sadeh encourages Accolade shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Accolade and its board.

SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies.

Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE , Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ: ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary care, clinical weight management services, and mental health support from leading providers.

NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Accolade (NASDAQ: ACCD) and its board of directors concerning the proposed acquisition of the company by Transcarent. Stockholders will receive $7.03 for each share of Accolade stock that they hold.

Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considera.

Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.